Erin O'Brien

Some of the more severe ADHD symptoms noted were depression/withdrawal, problems with socialization.

Top-line data for study is expected in late 2022, early 2023.

Physical activity, marital status among factors contributing to complete mental health among participants.

Approval comes 1 year after the drug was approved for the treatment of ADHD in children and adolescents.

Strategy highlights plans of action to address untreated addiction, overdose epidemic.

The most common issues during the COVID-19 pandemic included stress, anxiety.

Catch up on all the latest from the American Pharmacists Association (APhA) Annual Meeting & Exposition.

The warnings cite consumer risks, as well as FD&C, RHA violations.

Evidence review focuses on bipolar disorder, psychosis, and major depression.

In Season 5, the psychiatric community weighed in on everything from finding meaning in music to the importance of mindfulness.

Study supports evidence for long-term impairment in memory, executive function.

In honor of Women's History Month, our contributors celebrate the women who inspire them.

Although research is limited, the results are promising.

Research also finds surprising results in patients with bipolar affective disorder.

Catch up on all the latest in psychiatric comorbidities.

Results highlight the impact of education on patient understanding of potential adverse events.

Researchers explore the psychiatric and neurological etiologies of visual hallucinations.

Results are clinically significant for the treatment of patients with major depressive disorder.

Drug comparison has significant implications for dose- and substance-dependence.

Findings show relationship between binge eating and brain activation.

Psychiatric Times featured a wide variety of psychiatric issues and current events throughout February.

The experts weighed in on a wide variety of psychiatric issues for the Psychiatric Times February 2022 issue.

Respondents discussed COVID-19 conditions and mental health benefits.

Panelists presented 2 studies comparing evidence-based strategies for improved patient outcomes.

If approved, this will be the fourth indication for the drug, joining its approvals for episodes associated with bipolar I disorder and schizophrenia.

Catch up on all the latest in ADHD from the APSARD virtual 2022 Annual Meeting.

Obesity, antidepressants may also impact risk of death in this population.

SrLCs include sexual dysfunction and special considerations for pediatric and geriatric populations.

Associated outcomes include higher rates of psychiatric hospitalization and mortality.

Study also identifies prevalence of specific behavioral addictions in these individuals.